These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 19513632

  • 1. Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE.
    Fontaine P, Gin H, Pinget M, Thivolet C, Hanaire H, Robert JJ, Marre M, Venkatanarasimhachar S.
    Adv Ther; 2009 May; 26(5):535-51. PubMed ID: 19513632
    [Abstract] [Full Text] [Related]

  • 2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 3. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 4. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 5. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S, PREDICTIVE Turkey Study Group.
    Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
    [Abstract] [Full Text] [Related]

  • 6. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
    Chacra AR, Kipnes M, Ilag LL, Sarwat S, Giaconia J, Chan J, COMPLETE T1D investigators.
    Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
    [Abstract] [Full Text] [Related]

  • 7. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 8. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 9. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).
    Philis-Tsimikas A.
    Expert Opin Pharmacother; 2008 Aug; 9(12):2181-95. PubMed ID: 18671472
    [Abstract] [Full Text] [Related]

  • 10. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
    Sreenan S, Virkamäki A, Zhang K, Hansen JB, PREDICTIVE study group.
    Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
    [Abstract] [Full Text] [Related]

  • 12. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E, Lang H, Roberts A.
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [Abstract] [Full Text] [Related]

  • 13. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
    Kvapil M.
    Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
    [Abstract] [Full Text] [Related]

  • 14. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M, Pinget M, Gin H, Thivolet C, Hanaire H, Robert JJ, Fontaine P.
    Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
    [Abstract] [Full Text] [Related]

  • 15. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
    Liebl A, Wilhelm B, Kaiser M.
    MMW Fortschr Med; 2012 Dec 17; 154 Suppl 4():102-9. PubMed ID: 23326928
    [Abstract] [Full Text] [Related]

  • 16. Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial.
    Selam JL, Meneghini LF.
    Adv Ther; 2009 Feb 17; 26(2):194-207. PubMed ID: 19259629
    [Abstract] [Full Text] [Related]

  • 17. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.
    Diabetes Care; 2003 Mar 17; 26(3):590-6. PubMed ID: 12610006
    [Abstract] [Full Text] [Related]

  • 18. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, PREFER Study Group.
    Diabetes Obes Metab; 2009 Jan 17; 11(1):45-52. PubMed ID: 18643839
    [Abstract] [Full Text] [Related]

  • 19. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.
    Lüddeke HJ, Sreenan S, Aczel S, Maxeiner S, Yenigun M, Kozlovski P, Gydesen H, Dornhorst A, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2007 May 17; 9(3):428-34. PubMed ID: 17391171
    [Abstract] [Full Text] [Related]

  • 20. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K.
    Vasc Health Risk Manag; 2010 Jun 01; 6():399-410. PubMed ID: 20539842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.